Skip to main navigation
Skip to main content
  • Investors & Media
    • Overview
    • Newsroom
    • Events
    • Financial Information
    • Stock Information & Analyst Coverage
    • FAQs
  • Careers
  • Partnerships & Business Development
  • esperionscience.com
  • Contact Us
  • Investors & Media
    • Overview
    • Newsroom
    • Events
    • Financial Information
    • Stock Information & Analyst Coverage
    • FAQs
  • Our Company
    • About Us
    • Leadership Team
    • Board of Directors
    • Ethics and Compliance
    • Corporate Governance & Committee Composition
  • Patients
    • Cholesterol Education
    • Unmet Need
    • Patient Advocacy and Resources
  • Products
  • Science
    • Scientific Advisory Board
    • Pipeline
    • Clinical Trials
    • Expanded Access
    • Grants
  • Partnerships & Business Development
/investor-relations/newsroom

Newsroom

Esperion to Participate in Upcoming September Investor Conferences
Aug 30, 2022
PDF Version
Esperion Announces Bempedoic Acid (NEXLETOL®) Recommended as Oral Non-Statin Therapy for LDL-Cholesterol Lowering in American College of Cardiology Expert Consensus Decision Pathway
Aug 26, 2022
PDF Version
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aug 04, 2022
PDF Version
Esperion Reports Second Quarter 2022 Financial Results and Provides Company Update
Aug 02, 2022
PDF Version
Esperion Announces Establishment of Scientific Advisory Board to Support Pipeline and Life Cycle Management
Jul 25, 2022
PDF Version

Pagination

  • First page « first
  • Previous page ‹ previous
  • …
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Current page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • …
  • Next page next ›
  • Last page last »

-

Media Information

To speak with a member of our PR team, or to schedule an interview, please contact Esperion Corporate Communications by phone at +1 734-864-6774, or by email at corporateteam@esperion.com.

Leadership Information


Investors:
Alexis Callahan
investorrelations@esperion.com
(406) 539-1762

Corporate Inquiries & Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438

Page Tools

Our Company

  • Our Company
    • About Us
    • Leadership Team
    • Board of Directors
    • Ethics and Compliance
    • Corporate Governance & Committee Composition

Patients

  • Patients
    • Cholesterol Education
    • Unmet Need
    • Patient Advocacy and Resources

Products

  • Products

Science

  • Science
    • Scientific Advisory Board
    • Pipeline
    • Clinical Trials
    • Expanded Access
    • Grants

Careers

  • Careers

Partnerships & Business Development

  • Partnerships & Business Development

Investors & Media

  • Investors & Media
    • Overview
    • Newsroom
    • Events
    • Financial Information
    • Stock Information & Analyst Coverage
    • FAQs

esperionscience footer

  • esperionscience.com

Contact Us

  • Contact Us

All trademarks and trade names are the property of their respective owners.

© 2023 Esperion Therapeutics, Inc. All rights reserved. 05/20 US-CRP-2000082

Utility

  • Privacy Policy
  • Terms of Use
  • Accessibility Statement
  • Social Media Community Guidelines

Search

Share this page